Wade Julia, Donovan Jenny, Lane Athene, Davis Michael, Walsh Eleanor, Neal David, Turner Emma, Martin Richard, Metcalfe Chris, Peters Tim, Hamdy Freddie, Kockelbergh Roger, Catto James, Paul Alan, Holding Peter, Rosario Derek, Kynaston Howard, Rowe Edward, Hughes Owen, Bollina Prasad, Gillatt David, Doherty Alan, Gnanapragasam Vincent J, Paez Edgar
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
BMJ Open. 2020 Sep 9;10(9):e036024. doi: 10.1136/bmjopen-2019-036024.
Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men's strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supportive care.
Longitudinal serial in-depth qualitative interviews every 2-3 years for a median 7 (range 6-14) years following diagnosis.
Four centres within the UK Protect trial.
Purposive sample of 20 men with localised PCa: median age at diagnosis 64 years (range 52-68); 15 (75%) had low-risk PCa; 12 randomly allocated to, 8 choosing AM. Eleven men continued with AM throughout the study period (median 7 years). Nine received radical treatment after a median 4 years (range 0.8-13.8 years).
AM: 3-monthly serum prostate-specific antigen (PSA)-level assessment (year 1), 6-12 monthly thereafter; increase in PSA ≥50% during previous 12 months or patient/clinician concern triggered review.
Thematic analysis of 73 interviews identified strategies to accommodate uncertainty and anxiety of living with untreated cancer; implications for patient care.
Men sought clarity, control or reassurance, with contextual factors mediating individual responses. Trust in the clinical team was critical for men in balancing anxiety and facilitating successful management change/continued monitoring. Only men from ProtecT were included; men outside ProtecT may have different experiences.
Men looked to clinicians for clarity, control and reassurance. Where provided, men felt comfortable continuing AM or having radical treatments when indicated. Clinicians build patient trust by clearly describing uncertainties, allowing patients control wherever possible and being aware of how context influences individual responses. Insights indicate need for supportive services to build trust and patient engagement over the long term.
ISRCTN20141297; Pre-results.
主动监测(AS)使低风险、局限性前列腺癌(PCa)男性避免进行根治性治疗,除非病情进展;但缺乏可靠的确定病情进展的AS方案给男性和临床医生带来了不确定性。本研究调查了男性长期应对主动监测(AM,前列腺癌检测与治疗试验中的一种监测策略)不确定性的策略以及对优化支持性护理的影响。
诊断后每2 - 3年进行一次纵向系列深入定性访谈,中位时间为7年(范围6 - 14年)。
英国前列腺癌检测与治疗试验中的四个中心。
20名局限性PCa男性的目的性样本:诊断时中位年龄64岁(范围52 - 68岁);15名(75%)患有低风险PCa;12名随机分配至,8名选择AM。11名男性在整个研究期间持续接受AM(中位7年)。9名在中位4年(范围0.8 - 13.8年)后接受了根治性治疗。
AM:第1年每3个月进行一次血清前列腺特异性抗原(PSA)水平评估,此后每6 - 12个月一次;前12个月内PSA升高≥50%或患者/临床医生担忧引发复查。
对73次访谈进行主题分析,确定了应对未治疗癌症带来的不确定性和焦虑的策略以及对患者护理的影响。
男性寻求明确性、控制权或安心感,情境因素调节个体反应。对临床团队的信任对于男性平衡焦虑和促进成功的管理变更/持续监测至关重要。仅纳入了来自前列腺癌检测与治疗试验的男性;试验外的男性可能有不同经历。
男性期望临床医生提供明确性、控制权和安心感。若能做到这些,男性在必要时继续接受AM或进行根治性治疗会感到安心。临床医生通过清晰描述不确定性、尽可能让患者拥有控制权并了解情境如何影响个体反应来建立患者信任。研究结果表明需要长期提供支持性服务以建立信任和患者参与度。
ISRCTN20141297;预结果。